NYSE:ANVS Annovis Bio (ANVS) Stock Price, News & Analysis $1.92 +0.03 (+1.32%) Closing price 05/29/2026 03:59 PM EasternExtended Trading$1.96 +0.04 (+1.87%) As of 05/29/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Annovis Bio Stock (NYSE:ANVS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Annovis Bio alerts:Sign Up Key Stats Today's Range$1.89▼$1.9750-Day Range$1.59▼$2.6752-Week Range$1.54▼$5.50Volume959,199 shsAverage Volume1.20 million shsMarket Capitalization$66.70 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingHold Company Overview Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage biotechnology company headquartered in Tampa, Florida, focused on the discovery and development of small molecule therapeutics for neurodegenerative and neuroinflammatory disorders. Leveraging a proprietary platform that targets protein trafficking and translational dysregulation, Annovis aims to restore cellular homeostasis by modulating the production and clearance of disease-related proteins. The company’s pipeline is designed to address critical pathways implicated in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and other central nervous system conditions. The company’s lead asset, ANVS401 (Posiphen®), is an oral small molecule that has been evaluated in Phase 1 and Phase 2 clinical trials to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer’s patients. Preclinical studies suggest that this mechanism may also have applications in mitigating neuroinflammation. In addition to ANVS401, Annovis is advancing a second-generation program, ANVS520, which is aimed at lowering pathological tau and alpha-synuclein aggregates, key drivers of neurodegeneration in Alzheimer’s and Parkinson’s diseases. Both candidates reflect the company’s strategy of targeting multiple disease pathways with a single therapeutic approach. Annovis Bio conducts its clinical trials in North America and Europe, collaborating with academic research centers and contract research organizations to explore safety, pharmacodynamics and biomarker endpoints. The company’s leadership team brings together expertise in neurology, medicinal chemistry and drug development, with a commitment to translating early-stage research into viable treatments. As a publicly traded entity, Annovis continues to engage with scientific and investor communities to advance its programs toward potential regulatory approval.AI Generated. May Contain Errors. Read More Annovis Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreANVS MarketRank™: Annovis Bio scored higher than 57% of companies evaluated by MarketBeat, and ranked 473rd out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingAnnovis Bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAnnovis Bio has a consensus price target of $13.50, representing about 601.3% upside from its current price of $1.93.Amount of Analyst CoverageAnnovis Bio has only been the subject of 2 research reports in the past 90 days.Read more about Annovis Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Annovis Bio is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annovis Bio is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnovis Bio has a P/B Ratio of 21.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Annovis Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.04% of the float of Annovis Bio has been sold short.Short Interest Ratio / Days to CoverAnnovis Bio has a short interest ratio ("days to cover") of 4.85.Change versus previous monthShort interest in Annovis Bio has recently decreased by 2.95%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnnovis Bio does not currently pay a dividend.Dividend GrowthAnnovis Bio does not have a long track record of dividend growth. News and Social Media2.5 / 5News SentimentN/A News SentimentAnnovis Bio has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Annovis Bio this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for ANVS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.8 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $1,641,743.00 in company stock, which represents 2.4616% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Annovis Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,641,743.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.80% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.83% of the stock of Annovis Bio is held by institutions.Read more about Annovis Bio's insider trading history. Receive ANVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANVS Stock News HeadlinesAnnovis Bio Regains NYSE Listing ComplianceMay 26, 2026 | globenewswire.comAnnovis Bio (NYSE:ANVS) Director Michael Hoffman Buys 76,344 SharesMay 22, 2026 | insidertrades.comJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.May 30 at 1:00 AM | Brownstone Research (Ad)Annovis Bio slips after pricing $15M equity offeringMay 20, 2026 | seekingalpha.comAnnovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying WarrantsMay 20, 2026 | globenewswire.comAnnovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying WarrantsMay 19, 2026 | globenewswire.comAnnovis Provides Corporate Updates and Reports First Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comAnnovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026May 7, 2026 | globenewswire.comSee More Headlines ANVS Stock Analysis - Frequently Asked Questions How have ANVS shares performed this year? Annovis Bio's stock was trading at $3.43 at the start of the year. Since then, ANVS stock has decreased by 43.9% and is now trading at $1.9250. How were Annovis Bio's earnings last quarter? Annovis Bio, Inc. (NYSE:ANVS) announced its earnings results on Friday, May, 15th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.24. When did Annovis Bio IPO? Annovis Bio (ANVS) raised $12 million in an IPO on Thursday, November 18th 2021. The company issued 2,000,000 shares at $6.00 per share. Who are Annovis Bio's major shareholders? Top institutional investors of Annovis Bio include Renaissance Technologies LLC (1.00%) and Bank of New York Mellon Corp (0.05%). Insiders that own company stock include Michael B Hoffman and Maria-Luisa Maccecchini. View institutional ownership trends. How do I buy shares of Annovis Bio? Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Annovis Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annovis Bio investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings5/15/2026Today5/30/2026Next Earnings (Estimated)8/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ANVS's financial health is in the Yellow zone, according to TradeSmith. ANVS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSE:ANVS CIK1477845 Webwww.annovisbio.com Phone610-727-3913FaxN/AEmployees3Year Founded2008Price Target and Rating Average Price Target for Annovis Bio$13.50 High Price Target$17.00 Low Price Target$10.00 Potential Upside/Downside+601.3%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-318.08% Return on Assets-215.47% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book21.39Miscellaneous Outstanding Shares34,647,000Free Float27,440,000Market Cap$66.70 million OptionableOptionable Beta1.26 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NYSE:ANVS) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe grid just blinked redOn May 4, 2026, NERC issued only the third Level 3 grid warning in history - the highest grade short of an act...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
